# Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

> **NCT01350401** · PHASE1,PHASE2 · TERMINATED · sponsor: **Adaptimmune** · enrollment: 4 (actual)

## Conditions studied

- Melanoma

## Interventions

- **GENETIC:** Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T

## Key facts

- **NCT ID:** NCT01350401
- **Lead sponsor:** Adaptimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-01
- **Primary completion:** 2016-02-17
- **Final completion:** 2018-03-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01350401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01350401, "Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01350401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*